Ryan Daws's most recent trade in enGene Holdings Inc was a trade of 220,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| enGene Holdings Inc | Ryan Daws | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Ryan Daws | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 280,000 | 280,000 | - | - | Stock Option (Right to Buy) | |
| enGene Holdings Inc | Ryan Daws | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 232,000 | 232,000 | - | - | Stock Option (Right to Buy) |